TherapeuticsMD (TXMD) Asset Writedowns and Impairment (2012 - 2025)
TherapeuticsMD (TXMD) posted Asset Writedowns and Impairment of $1.3 million for Q1 2025, up 17914.29% on a QoQ basis from $7000.0 in Q4 2024.
TherapeuticsMD (TXMD) Asset Writedowns and Impairment (2012 - 2025) Analysis & Trends
TherapeuticsMD's Asset Writedowns and Impairment history runs 14 years deep, the most recent figure standing at $1.3 million for Q1 2025.
- Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $1.3 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $1.3 million (changed N/A YoY) and the FY2024 annual result came in at $1.3 million, changed N/A from the prior year.
- Asset Writedowns and Impairment was $1.3 million for Q1 2025 at TherapeuticsMD, up from $7000.0 in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $1.3 million in Q1 2025 and bottomed at -$7000.0 in Q4 2021.
- A 5-year average of $266888.9 and a median of $215000.0 in 2021 frame the typical range for Asset Writedowns and Impairment.
- Peak annual rise in Asset Writedowns and Impairment reached 462.08% in 2021, while the deepest fall reached 101.4% in 2021.
- TherapeuticsMD's Asset Writedowns and Impairment stood at -$7000.0 in 2021, then jumped by 3928.57% to $268000.0 in 2022, then sank by 77.99% to $59000.0 in 2023, then slumped by 88.14% to $7000.0 in 2024, then soared by 17914.29% to $1.3 million in 2025.
- Business Quant data shows TXMD's Asset Writedowns and Impairment at $1.3 million in Q1 2025, $7000.0 in Q4 2024, and $59000.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | TherapeuticsMD | 280,159.99 | -8.14 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 1.26 Mn |
| Mar 31, 2025 | 1.26 Mn |
| Dec 31, 2024 | 7,000.00 |
| Dec 31, 2024 | 7,000.00 |
| Mar 31, 2023 | 59,000.00 |
| Mar 31, 2023 | 59,000.00 |
| Jun 30, 2022 | 268,000.00 |
| Jun 30, 2022 | 268,000.00 |
| Mar 31, 2022 | 274,000.00 |
| Mar 31, 2022 | 274,000.00 |
| Dec 31, 2021 | -7,000.00 |
| Dec 31, 2021 | -7,000.00 |
| Sep 30, 2021 | 95,000.00 |
| Sep 30, 2021 | 95,000.00 |
| Jun 30, 2021 | 215,000.00 |
| Jun 30, 2021 | 215,000.00 |
| Mar 31, 2021 | 230,000.00 |
| Mar 31, 2021 | 230,000.00 |
| Dec 31, 2020 | 500,000.00 |
| Dec 31, 2020 | 500,000.00 |